ThermoGenesis Holdings, Inc. Gains 43.2%

ThermoGenesis Holdings, Inc. (THMO:NASDAQ) shot up at $6, representing a gain of 43.2%. On Thu, Mar 16, 2023, THMO:NASDAQ touched a New 2-Week High of $6. The stock appeared on our News Catalysts scanner on Thu, Mar 16, 2023 at 09:10 AM in the 'PRIVATE PLACEMENT' category. From Thu, Mar 02, 2023, the stock recorded 30.00% Up Days and 27.27% Green Days
About ThermoGenesis Holdings, Inc. (THMO:NASDAQ)
ThermoGenesis Holdings, Inc. is clinical-stage biotechnology company. The company is engaged in developing and manufacturing automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. The company's device division, ThermoGenesis Corp, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. ThermoGenesis Holdings, Inc.'s clinical development division is leveraging its proprietary AutoXpress technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the immuno-oncology, vascular, cardiology and orthopedic markets.
Top 10 Gainers:
- Corbus Pharmaceuticals Holdings, Inc. (CRBP:NASDAQ), 97.59%
- OncoCyte Corporation (OCX:NASDAQ), 51.5%
- Baudax Bio, Inc. (BXRX:NASDAQ), 44.36%
- ThermoGenesis Holdings, Inc. (THMO:NASDAQ), 43.2%
- PureCycle Technologies Inc. (PCT:NASDAQ), 39.41%
- Lipella Pharmaceuticals Inc. (LIPO:NASDAQ), 39.11%
- Kintara Therapeutics Inc. (KTRA:NASDAQ), 34.04%
- Peak Bio Inc Com (PKBO:NASDAQ), 31.56%
- Genelux Corporation (GNLX:NASDAQ), 27.78%
- Boqii Holding Limited American Depositary Shares representing Class A (BQ:NYSE), 25.81%